Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI ) by John F. Heerdink, Jr. 3 days ago Read more Register Now: Tribe Public’s 30-Minute Deep Dive on Making EoE a Once‑a‑Year Appointment -( $EPRX $SNY $IBB $XBI ) by John F. Heerdink, Jr. 5 days ago Read more Eupraxia’s EP-104 Is Quietly Auditioning for a Starring Role In Eosinophilic Esophagitis -( $EPRX $SNY $TAK $IBB $XBI ) by John F. Heerdink, Jr. March 25, 2026 Read more Eupraxia’s Six-Month Data Put EP-104GI On The Map – And EPRX On More Screens -( $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. March 17, 2026 Read more From Under the Radar to Over the Moon? Raymond James Puts a Strong‑Buy Spotlight on Eupraxia – $EPRX $IBB $SNY $XBI ) by John F. Heerdink, Jr. March 9, 2026 Read more Eupraxia Steps Into the Spotlight: AAAAI 2026 Puts EoE Back on the Growth Map -( $EPRX $SNY $REGN $IBB $XBI ) by John F. Heerdink, Jr. March 2, 2026 Read more Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY) by John F. Heerdink, Jr. February 21, 2026 Read more U.S. Stocks Propel Forward On Monday – February 9, 2026 -( $AVGO $DV $FLYX $META $NOK $NVDA $OKLO $OPEN $ORCL $PLTR $RIO $TSLA $TSM Rise!) by John F. Heerdink, Jr. February 10, 2026 Read more Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI ) by John F. Heerdink, Jr. February 9, 2026 Read more Dow Breaks 50,000 as Wall Street Limps, Then Leaps Into the Weekend – February 6, 2026 -( $DIA $EPRX $FLYX $LLY $MCD $MANE $MODD $NOK $RIO Rise!) by John F. Heerdink, Jr. February 6, 2026 Read more Read more
